Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season

International Journal of Environmental Research and Public Health

F.Xavier López-Labrador¹  Joan Puig-Barber๠ Javier García-Rubio¹  Beatriz Mengual-Chuliá¹  Javier Díez-Domingo¹  Ainara Mira-Iglesias¹  Germán Schwarz-Chavarri²  Mario Carballido-Fernández³  Miguel Tortajada-Girbés⁴  Joan Mollar-Maseres⁵ 

[1] Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain;Hospital General Universitario de Alicante, 03010 Alicante, Spain;Hospital General Universitario de Castellón, 12004 Castellón, Spain;Hospital Universitario Doctor Peset, 46017 Valencia, Spain;Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain;

关键词: influenza;    vaccine;    effectiveness;    hospitalizations;    waning;    surveillance;   

DOI  :  10.3390/ijerph18031129

来源: DOAJ

【 摘 要 】

Influenza vaccination is annually recommended for specific populations at risk, such as older adults. We estimated the 2018/2019 influenza vaccine effectiveness (IVE) overall, by influenza subtype, type of vaccine, and by time elapsed since vaccination among subjects 65 years old or over in a multicenter prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Information about potential confounders was obtained from clinical registries and/or by interviewing patients and vaccination details were only ascertained by registries. A test-negative design was performed in order to estimate IVE. As a result, IVE was estimated at 46% (95% confidence interval (CI): (16%, 66%)), 41% (95% CI: (−34%, 74%)), and 45% (95% CI: (7%, 67%)) against overall influenza, A(H1N1)pdm09 and A(H3N2), respectively. An intra-seasonal not relevant waning effect was detected. The IVE for the adjuvanted vaccine in ≥75 years old was 45% (2%, 69%) and for the non-adjuvanted vaccine in 65–74 years old was 59% (−16%, 86%). Thus, our data revealed moderate vaccine effectiveness against influenza A(H3N2) and not significant against A(H1N1)pdm09. Significant protection was conferred by the adjuvanted vaccine to patients ≥75 years old. Moreover, an intra-seasonal not relevant waning effect was detected, and a not significant IVE decreasing trend was observed over time.

【 授权许可】

Unknown